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Summary
Background: The prevalence of HIV/hepatitis B virus (HBV) co-infection in South Africa ranges
from 4.8% to17% using the standard marker surface antigen (hepatitis B surface antigen, HBsAg)
for chronic active HBV infection. However, sensitive molecular techniques for detecting HBV DNA
in serum can detect occult HBV infection. We report the first observational prospective study of
occult HBV infection in HIV-positive people in South Africa.
Methods: Five hundred and two patients attending an urban hospital were screened for HBVusing
serological testing for HBsAg, core antibody (anti-HBc), and surface antibody (anti-HBs). DNAwas
analyzed using real-time quantitative PCR to determine the HBV viral load.
Results: Of the502participants,24(4.8%)wereHBsAg-positiveand53(10.6%)werepositiveforanti-
HBc alone. Of these 53, screening for occult disease was carried out in 43, of whom 38 (88.4%) were
positive. The mean HBV viral load was 2.8  104 copies/ml (range 1  102 to 1  106 copies/ml).
Conclusions: Combining the participants with positive HBsAg and occult HBV DNA results, the
prevalence of HBV increases from 4.8% (HBsAg alone) to 12.4%. While the clinical impact of occult
HBV infection is unclear, consideration should be given to changing the guidelines to recommend
dual HBV therapy for the treatment of co-infected patients in the developing world.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Both HIVand hepatitis B virus (HBV) infections are endemic in
sub-Saharan Africa.1,2 Recent studies have shown the pre-
valence of HIV/HBV co-infection (using hepatitis B surface
antigen (HBsAg) as a marker for HBV) in South Africa ranging
from 4.8% to 17%, depending on the population studied.3—5
HIV/HBV co-infection rates from the Themba Lethu Clinic
cohort in Johannesburg have been reported previously.5
Serological markers have been the standard method of diag-
nosis of HBV infection for more than 30 years. The wider
availability during recent years of very sensitive molecular
biology techniques for detecting HBV DNA in serum and liver
tissue has increased attention to occult (silent) HBV infec-
tion. Occult HBV DNA is defined as HBV DNA found in liver or
serum in HBsAg-negative patients. Occult HBV infection has
important implications when considering the transmission of
the virus and complications of chronic HBV infection such as
cirrhosis and hepatocellular carcinoma. Further investigation
of occult HBV DNA infection in HIV-seropositive patients is
needed given the more rapid progress towards chronic liver
disease in people with HIV/HBV co-infection, the possible
complications of antiretroviral therapy (ART), perinatal
transmission of HBV from mother to child, and the risk of
HBV transmission through liver transplants.6
Recent advances in antiviral therapy directed at both HIV
and HBV have led to the development of the World Health
Organization (WHO) guidelines for standardized regimens to
treat both diseases. These include the recommendation that
HIV/HBV co-infected patients be treated with an antiretro-
viral (ARV) regimen that contains three drugs, two of which
are effective against HBV as well as HIV.7
Occult HBV infection needs to be considered when estab-
lishing the prevalence of HIV/HBV co-infection in different
populations. This information is already available in some
countries.8—10 However, there has only been a single study
evaluating occult HBV in sub-Saharan Africa. This was a
retrospective laboratory-based analysis on stored serum,
which found that one third (5/15) of HIV-positive patients
whose serumwas negative for HBsAg but positive for antibody
to the core antigen (anti-HBc) were also positive for HBV DNA
(occult HBV infection was present). In contrast, none of the
31 HIV-negative patients with anti-HBc alone tested positive
for occult HBV DNA.11 We report the first observational
prospective study of HIV-seropositive people in sub-Saharan
Africa. Our study used volunteers from the US President’s
Emergency Plan for AIDS Relief (PEPFAR)-supported Themba
Lethu Clinic in Johannesburg, South Africa.
Methods
Study design and subjects
HBV serology is not standard of care in the evaluation of HIV-
seropositive people in the South Africa National Department
of Health’s (DoH) Comprehensive Care, Management and
Treatment Program for HIV/AIDS.12 Patients from the HIV
Themba Lethu Clinic, which is located in a secondary govern-
ment academic hospital in Johannesburg, South Africa and is
affiliated to the University of the Witwatersrand, were
invited to participate in this study. The study participants,who had already been diagnosed with HIV, were attending an
educational session regarding HIV and ART. In this session,
HBV infection was discussed and inclusion in the seropreva-
lence study was offered. The patients who decided to parti-
cipate in the study signed a written consent and most had
their hepatitis B serology done after the educational session.
These patients were about to initiate ART in accordance with
public sector guidelines (i.e., with a CD4 count <200 cells/
mm3 and/or WHO stage 4).12 Participants needed to be
treatment-naı¨ve and able to initiate an ART regimen that
included lamivudine. If the patients were found to be HBsAg-
positive, they were asked to return for initiation of ARVs and
followed for 6 months. HBsAg-negative participants were
referred to the Themba Lethu Clinic or another clinic of
their choice for ART. The study was approved by the Uni-
versity of Witwatersrand Ethics Committee and the Saint
Louis University Internal Review Board.
HBV serology
Routine laboratory investigations for HIV monitoring were
performed according to the public sector guidelines. Hepa-
titis B serology included HBsAg, anti-HBc, and antibody to the
surface antigen (anti-HBs) using the Axsym assay from
Abbott, which uses microparticle enzyme immunoassay
(MEIA) methodology. The hepatitis B serology testing was
conducted as part of the primary study, which has been
reported previously.5
Real-time PCR quantification of HBV DNA
HBV DNA from only the 43 HIV-positive samples with isolated
anti-HBc were analyzed by real-time quantitative PCR using
the ABI Prism 7500 (Applied Biosystems, USA) to determine
the HBV viral load. DNA was extracted from 50 ml of serum
using the QIAamp MinElute Virus Spin kit (Qiagen, Germany)
according to the manufacturer’s instructions, and eluted into
50 ml of nuclease free water. PCR primers, HBV-Taq1 and HBV-
Taq2 as well as the FAM/TAMRA labeled TaqMan BS-1 probe
were used as described previously.13 PCR reactions were
performed in a 50 ml total volume using 25 ml of 2 TaqMan
Universal PCR Master Mix (Applied Biosystems, USA), 300 nM
HBV-Taq1 forward primer, 300 nM HBV-Taq2 reverse primer,
200 nM TaqMan BS-1 probe, and 2 ml of DNA. PCR conditions
for HBV detection were as follows: 1 cycle of 2 min at 50 8C
and 10 min at 95 8C, followed by 45 cycles of 95 8C for 15 s
and 60 8C for 1 min. A plasmid encoding a single genome of
HBV DNA was run to obtain a linear standard curve with an
observed range of 103 to 108 copies in agreement with
previous reports for this primer/probe set.13 The second
WHO International Standard for HBV Nucleic Acid Amplifica-
tion Techniques, product code 97/750, which has a final
concentration of 1  106 IU/ml, was obtained from the
National Institute for Biological Standards and Controls
(NIBSC; Hertfordshire, UK) and used as a positive control,
as well as to calibrate and align the standard curve. The
standard curve, blank, positive and negative controls, and
samples were all tested in duplicate. The measured IU/ml for
each reaction was calculated using the Ct (cycle threshold)
value of each PCR interpolated against the linear regression
of the standard curve. For each sample the duplicate average
value was multiplied by 4.7 to convert from IU/ml to copies/
Table 1 Hepatitis B seroprevalence study (N = 502).
Number %
HBsAg-positive 24 4.8
anti-HBc isolateda 53 10.6
anti-HBs + anti-HBc 124 24.7
anti-HBs isolatedb 13 2.6
Hepatitis B serology negative 288 57.4
HBsAg, hepatitis B surface antigen; anti-HBc, hepatitis B core
antibody; anti-HBs, hepatitis B surface antibody. No hepatitis e
antigen was obtained on these screening samples.
a Isolated anti-HBc describes serology that is positive for anti-
HBc only and negative for anti-HBs and HBsAg.
b Isolated anti-HBs describes serology that is positive for anti-
HBs only and negative for anti-HBc and HBsAg.
Table 2 Sample viral load results.
Viral load %
Below detectable 12%
1  102 7%
1  103 62%
1  104 12%
1  105 5%
1  106 2%
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copies/ml. All the samples underwent PCR assay testing
for hepatitis C virus (HCV) RNA using the Cobas Amplicor
HCV Monitor (Roche) methodology.14
Data collection
A complete demographic history was obtained from each
participant. The medical history was obtained from both
the participant and the medical chart held in Therapy
edge-HIV, an electronic medical data system. Laboratory
data were collected from the medical chart. The data col-
lected were entered/stored on site in an Access database by
the medical research staff at the Clinical HIV Research Unit
(CHRU). The seroprevalence database was also designed by
CHRU staff.
Statistical analysis
All statistical analysis was done using Stata 9 statistical
software. Descriptive statistics were done, calculating
means and standard deviations for normally distributed data,
median and interquartile ranges for data that were not
normally distributed. The Wilcoxon rank sum test was used
to test the association between HBV viral load and the
categorical variables age group, CD4 count, and gender.
The relationship between the log of HBV viral load and
gender, CD4 count, and age was investigated using linear
regression. In this analysis of 38 individuals, assuming an
alpha of 0.05, we had 80% power to detect a 3 log difference
in HBV viral load between CD4 cell count groups, a 1.75 log
difference in HBV viral load between age groups, and a 1.73
log difference in HBV viral load between the genders.
Results
A total of 502 people agreed to the HBV screening and signed
a written informed consent, after the educational session.
Common reasons for not participating included additional
time needed to listen to the education on hepatitis B, poor
understanding of the study, refusal to have extra blood
drawn, and feeling too ill to participate in the study.
Of the parent cohort, 24 (4.8%) were positive for HBsAg
with no association to age, sex, or CD4 count.5 The complete
serological results of this study are shown in Table 1. A total
of 53 out of 502 (10.6%) participants were found to have
isolated anti-HBc. These specimens were eligible for inclu-
sion in the DNA assessment for occult infection. Seven
patients had signed consent in the parent study with the
proviso that they did not want to store blood for further
testing, and three serum samples were not available for
further testing. A final total of 43 serum samples were
evaluated for occult HBV DNA. Of these 43 samples, 38
(88.4%) were positive for HBV DNA on real-time PCR (see
Table 2). The mean HBV viral load was 2.8  104 copies/ml
(range 1  102 to 1  106 copies/ml). The viral copy number
was 1  102 copies/ml in 7% of the patients, 1  103 copies/
ml in 62%, 1  104 copies/ml in 12%, 1  105 copies/ml in 5%,
and 1  106 copies/ml in 2%. Females constituted 56% (n = 24)
of the cohort. The average age of these patients was 39.98
years (SD 11.64); males were significantly older than females(44.32  14.14 vs. 36.55  7.95 years, respectively;
p = 0.0229). The mean CD4 count of participants was 49
cells/mm3 (SD 77.21). These results were consistent with
results from the larger cohort.5
Five patients (12%) had undetectable HBV viral loads and
were not included in further analysis, hence the final cohort
for analysis consisted of 38 patients. The median HBV viral
load of these patients was 2285 copies/ml (IQR = 1580, 8930).
If the HBsAg-positive patients were added to the occult HBV
DNA results, a prevalence rate of 12.4% was found (i.e., 24
HBsAg-positive patients + 38 occult HBV DNA = 62; 62/
502 = 12.4%).
Univariate analysis of the associations between HBV viral
load and categorical variables gender, CD4 count (CD4 count
<50 cells/mm3 vs. CD4 count 50 cells/mm3), and age group
(<40yearsvs.40years)usingWilcoxonranksumtests showed
no significant association between HBV viral load and the
exposure variables considered. The distribution of HBV viral
load was improved by log transformation. Multivariate linear
regression showed therewasno statistically significant associa-
tion between log HBV viral load and gender, CD4 count, or age.
Only one out of the 43 serum samples was positive for HCV
on PCR, which is consistent with previous prevalence studies
of HCV co-infection in South Africa.4,15
Discussion
To-date, this is the largest outpatient prospective study of
occult HBV infection in HIV-seropositive patients in South
Africa. The only previous report was a retrospective review
from the University of Limpopo of stored samples from HIV-
positive and negative people where 5/15 samples were found
to be positive for HBV DNA.11 A less sensitive assay, the High
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In contrast, we prospectively studied a cohort of outpatients
from an HIV urban clinic. Of the parent cohort, 4.8% (24/502)
were HBsAg-positive and therefore traditionally considered
to have chronic active hepatitis B. In the same cohort, 53/502
(10.6%) were found to be isolated anti-HBc-positive. We used
real-time PCR to evaluate the 43 available samples in which
HBsAg was negative but isolated anti-HBc was present. A
significant proportion (12.4%) of patients in this South African
urban ARV clinic were found to be co-infected with HBV, and
serology tests alone may not be adequate to identify HBV co-
infection in HIV-1-infected patients initiating ART.
The clinical impact of occult HBV in HIV-seropositive
patients has not been described in Africa, but a retrospective
analysis on this cohort is planned. The clinical significance of
occult hepatitis reported from Europe and North America has
been conflicting. In a cohort from Philadelphia no significant
increase in liver transaminases was seen after controlling for
alcohol exposure and hepatitis C.16 An Italian cohort found an
increase in liver complications measured by elevated liver
transaminases in HIV-seropositive patients who were co-
infected with occult HBV. A statistically significant increase
in hepatitic flares during the treatment and after the dis-
continuation of lamivudine was noted in these co-infected
patients when compared to HIV-seropositive patients who did
not have occult HBV DNA (64.7% vs. 24.6%, p < 0.005).17 If
occult HBV DNA in HIV is found to be clinically significant, the
overall prevalence of HIV/HBV co-infection has significant
consequences for the ARV treatment program in resource-
poor settings such as southern Africa.
The US Department of Health and Human Services (DHHS)
guidelines and WHO recommendations for the treatment of
HBV include the use of more than one medication active
against HBV in combination therapy for HIV infection. The
consequences of the high prevalence of HBV co-infection need
to be considered when resource-poor countries decide on the
antiviral therapy regimens to be used.7,18 Lamivudine, a
nucleoside analogue reverse transcriptase inhibitor, is active
against both HIV and HBV. Lamivudine is currently one of the
three medicines in the highly active antiretroviral therapy
(HAART) regimen prescribed by clinicians in resource-limited
settings. However, while HBV can be treated with lamivudine,
there are reports of treatment complications in cases of HIV/
HBV co-infection. In particular, the addition and/or removal of
lamivudine can cause liver inflammation and, on rare occa-
sions, liver failure.17,19 Another complication of using lamivu-
dine as the only anti-HBV agent in regimens given to HIV/HBV
co-infected patients is the development of resistance. The
incidence of lamivudine resistance in this situation is approxi-
mately 20% per year. The implication is that during the first
year of ARV treatment using lamivudine, most patients will
receive adequate treatment of their hepatitis B. However, by
the second year approximately 40% of these patients will have
developed resistance. These figures have led to changes in the
DHHS/WHO guidelines to recommend dual therapy for HIV/
HBV co-infection using either tenofovir/lamivudine or Truvada
(tenofovir/emtricitabine).7,18
Other possible aspects of clinical significance of occult HBV
DNA in HIV-seropositive patients besides ART treatment con-
siderations is in pregnancy. In many countries where the pre-
valence of hepatitis B is high, hepatitis B serology testing is not
standard of care in pregnancy; this is the case in South Africa.12Perinatal transmission of HBV is well described.20 How occult
HBV DNA in the HIV pregnant womanmight affect transmission
of HBVand HIV to the baby and how to treat occult HBV DNA in
HIV-seropositive pregnant women are unknown.
In addition, it has been shown that HCV RNA is found in HIV
patients who are positive for occult HBV.19 In this cohort, only
one sample was positive for HCV RNA. Our findings are
consistent with previous reports that HCV is seen in only
0.5—1% of the HIV population in South Africa.4,15 Co-infection
with HCV is not a marker or a risk factor for occult HBV in
isolated anti-HBc positive patients, as seen in other studies.16
Limitations of this study may include potential selection
bias, in that the average CD4 count of all patients recruited
into the parent study was below 200 cells/mm3. This is due to
current government guidelines on initiating ART in HIV-
infected persons in South Africa,12 so it is unclear what
the occult hepatitis B rate might be in patients who are more
immune competent. The lack of statistical significance in the
multivariate linear regression analysis between log HBV viral
load and gender, CD4 count, or age may be partly due to the
small sample size and consequent lack of statistical power.
Also, HBV DNA was only measured in the isolated anti-HBc-
positive sera, as this has been reportedmost commonly in HIV
patients. If the entire cohort were tested for HBV DNA, a
more accurate picture of occult DNA would be obtained.
Plans are underway for this testing in the future.
Conclusions
This study highlights the fact that HBsAg may not be an
effective tool for diagnosis of HIV/HBV co-infection in our
study population. It also demonstrates that the HIV/HBV co-
infection rate is significantly underestimated with the cur-
rent serology testing methods alone.
The WHO and the South African HIV Clinician’s Society
have recommended the use of tenofovir in combination with
either lamivudine or emtricitabine as first-line therapy in ARV
clinics in resource-limited countries due to the toxicity of
stavudine. We would like to add further support to these
recommendations. With the high prevalence of HBV co-infec-
tion in the HIV population in South Africa, treatment with
tenofovir/lamivudine as first-line therapy would not only
improve the safety and simplify HIV treatment, but would
also appropriately treat the patients co-infected with a
carcinogenic virus, HBV.
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